Skip to content

Early Outcome of Mechanochemical Endovenous Ablation

Mechanochemical Endovenous Ablation of Great Saphenous Vein Incompetence Using the ClariVeinTM Device: a Prospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01459263
Acronym
ClariVein-2
Enrollment
124
Registered
2011-10-25
Start date
2010-11-30
Completion date
2018-02-28
Last updated
2018-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicosis

Keywords

GSV, insufficiency, ClariVein device, safety, efficacy, QOL

Brief summary

More than 25 percent of the general population suffers from varicose veins, which has a considerable impact on quality of life. Nowadays endovenous treatment modalities for great saphenous incompetence are widely accepted. Mechanochemical endovenous ablation is a new tumescent-less technique, that combines mechanical endothelial damage using a rotating wire with the infusion of a liquid sclerosant. The current study aims at evaluating short and long term outcome after mechanochemical endovenous ablation.

Interventions

DEVICEClariVein

Using the ClariVein device, the GSV will be occluded.

Sponsors

St. Antonius Hospital
CollaboratorOTHER
Rijnstate Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Insufficiency of the GSV * Ultrasound criteria for endovenous treatment have been met: * Diameter GSV between 3-12 mm * No thrombus present at the GSV part to be treated * Signed informed consent * Patient willing to present at follow-up visits * Age \> 18 jaar

Exclusion criteria

* Patient is unable to give informed consent * Patient unable to present at all follow-up visits * Other treatment is more suitable for the treatment of the varicose veins than mechano-chemical ablation * Pregnancy and breast feeding * Known allergy/ contra indication for sclerotherapy * Previous ipsilateral surgical treatment of varicose veins * Deep venous vein thrombosis in medical history * Anticoagulant therapy

Design outcomes

Primary

MeasureTime frameDescription
Occlusion rate30 days, 1, 2, and 5 yearsThe percentage of GSV occluded

Secondary

MeasureTime frameDescription
Disease related quality of life30 days, 1, 2, and 5 yearsUsing the AVVQ (Aberdeen Varicose Vein questionnaire) the quality of life related to the disease will be evaluated at the mentioned time points.
Pain score during procedureperi-proceduralThe pain will be scored during procedure using the VAS score.
2-weeks post-procedure pain scoretwo weeksThe pain will be scored daily for two weeks after the procedure using the VAS score.
Health status30 days, 1, 2, and 5 yearsUsing the RAND 36-Item Short Form Health Survey (SF-36)the general health status will be evaluated at the mentioned time points. The SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
procedural complicationsduring procedureall complications related to the procedure will be evaluated at the mentioned time points.
post-procedural complications1 yearall complications related to the procedure will be evaluated at the mentioned time points.
recovery timetwo weeksThe time (in days) after the procedure until patients were able to restart daily activity/daily work

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026